Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1616||SWOG||A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent||Adult CIRB - Late Phase Emphasis||Available to Open|
|9922||ETCTN||A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance||Adult CIRB - Early Phase Emphasis||Available to Open|
|NRG-GY018||NRG||A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACNS1022||COG||A Phase II Randomized Trial of Lenalidomide (NSC # 703813; IND # 70116) in Pediatric Patients with Recurrent; Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|MAY2016-07-01||CLO-Mayo Clinic||Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis||Cancer Prevention and Control CIRB||Available to Open|
|S1714||SWOG||A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients||Cancer Prevention and Control CIRB||Available to Open|
|S0931||SWOG||EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy; A Phase III Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|UAZ2015-05-01||CLO-University of Arizona||A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys||Cancer Prevention and Control CIRB||Available to Open|
|GOG-0241||GOG||A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-CC004||NRG||Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire In Women With Breast or Gynecologic Cancer||Cancer Prevention and Control CIRB||Available to Open|